Dapagliflozin & Sitagliptin Combination Emerges as Effective Strategy in T2DM Care - Video
|
Overview
In this video, Dr Sunil Gupta, Diabetologist, CEO & MD, Sunil's Diabetes Care n' Research Centre Pvt. Ltd, Nagpur, discusses about the DIMETRIC study that provides a consensus-based evaluation of the dapagliflozin–sitagliptin combination for managing type 2 diabetes in India. Based on over 2,000 clinician-years of experience and a structured Likert-scale assessment, experts showed strong agreement across 16 clinical statements.
The combination demonstrated effective glycemic control along with notable cardiometabolic and renal benefits. Importantly, early initiation was widely recommended to overcome therapeutic inertia and improve long-term outcomes. Its dual-mechanism approach makes it a practical and evidence-driven option for diverse patient profiles in real-world settings.
As noted by Dr Sunil Gupta, this strategy supports more personalized and effective diabetes management in routine clinical practice.
Speakers
Dr Sunil Gupta is a leading diabetologist based in Nagpur and the CEO & MD of Sunil’s Diabetes Care n’ Research Centre. With extensive national and international recognition, he has contributed significantly to diabetes care, research, and education, with over 240 publications and multiple clinical trials to his credit. He is the National President-Elect of RSSDI (2026) and has received numerous prestigious awards, including global recognitions for his work in diabetology and community healthcare